30+ Series A Biotech Startups — $17.7B Raised, $60M Median

Series A biotech funding in 2025-2026 is flowing toward AI-driven drug discovery and novel therapeutic modalities at an extraordinary scale. Our dataset tracks 24 Series A biotech companies that raised a staggering $17.7B at a $60M median — the highest total-funding figure of any stage-industry cross-section in the dataset. Companies using AI to accelerate the drug development pipeline — from target identification to lead optimization — are raising the largest individual rounds, with some exceeding $100M. Gene therapy, cell therapy, and targeted protein degradation remain strong categories for institutional biotech investors. The regulatory pathway for AI-assisted drug development is becoming clearer, which is reducing risk for Series A investors. Specialized biotech funds like OrbiMed, Sofinnova, and Polaris Partners remain the most active. For sales teams, 24 companies with $17.7B in fresh capital are purchasing laboratory equipment, cloud computing for genomic analysis, compliance software, and scientific collaboration tools. Target the CSO for scientific tools and the COO/VP Operations for business operations software.